Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs acitretin in preventing progression of plaque psoriasis to psoriatic arthritis (retrospective cohort)
ChiCTR2500109183Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of secukinumab and acitretin in plaque psoriasis and psoriatic arthritis (PsA) (2 cohorts), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Imaging score. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
secukinumabacitretin
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on ChiCTR2500109183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109183.